Iodinated CT Contrast Agent for Early Cachexia Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for cancer cachexia and precachexia lack specificity and sensitivity, particularly in detecting adipose tissue changes, leading to delayed or inadequate treatment.
Innovation Solution
A CT scan using an iodinated CT contrast agent that can detect brown and beige adipose tissue (BAT) changes, administered orally or intravenously, to identify cachexia or precachexia by enhancing BAT activity and white adipose tissue (WAT) browning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for cachexia, then the diagnosis can be made, but the sensitivity and specificity are insufficient leading to delayed or inadequate treatment
Solution Approach 1:
The patent introduces a specific CT contrast agent as an intermediary substance that selectively accumulates in brown and beige adipose tissue. This contrast agent acts as a mediator between the imaging system and the adipose tissue, enabling direct visualization and quantification of BAT/WAT composition. The contrast agent's selective accumulation provides a clear signal that allows accurate detection of adipose tissue changes associated with cachexia, thereby improving diagnostic precision without significant time loss.
Solution Approach 2:
The patent utilizes contrast enhancement as a form of 'color change' in the CT imaging context. By administering the iodinated contrast agent, the brown and beige adipose tissue exhibits increased radiodensity (analogous to color change), making it visually distinguishable from other tissues. This contrast change enables clear visualization of adipose tissue distribution and composition, allowing accurate diagnosis of cachexia stages based on the degree of contrast enhancement observed in different tissue compartments.
2Difficulty of detecting and measuring
If no specific imaging method is used for adipose tissue, then the diagnosis relies on indirect markers, but this reduces detection capability for adipose tissue changes
Solution Approach 1:
The CT contrast agent serves as an intermediary that directly interacts with brown and beige adipose tissue, enabling their specific visualization. This intermediary substance accumulates selectively in BAT and WAT, providing a direct imaging signal that reveals adipose tissue composition and changes. This direct detection method eliminates the need to rely on indirect markers such as weight loss or muscle strength, thereby improving detection capability and preserving critical information about adipose tissue status.
Solution Approach 2:
The patent applies a universal imaging approach using CT scan that can detect multiple aspects of adipose tissue changes simultaneously. The same contrast agent and imaging modality can assess both brown and white adipose tissue composition, quantify their proportions, and monitor changes over time. This multi-functional capability allows comprehensive evaluation of adipose tissue status in cachexia without requiring multiple different diagnostic tests, thereby reducing information loss.
3Measurement precision
If standard CT scan without specific contrast agent is used, then the procedure is simple, but it cannot detect brown and beige adipose tissue changes
Solution Approach 1:
The patent modifies the CT imaging parameters by introducing a specific iodinated contrast agent formulation. This parameter change (adding the contrast agent) fundamentally alters the imaging capability, enabling detection of brown and beige adipose tissue that would be invisible or indistinguishable on a standard CT scan. The contrast agent's specific accumulation characteristics in BAT and WAT provide the necessary signal for precise detection, justifying the added procedural complexity through significant gains in detection precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early and accurate diagnosis of cachexia or precachexia through positive contrast enhancement, allowing timely intervention and improving patient outcomes.
Implementation Method 1
diagnosis of cachexia or precachexia is performed by establishing positive or increased enhancement of BAT and/or beige adipose tissue
Data Source
AI summary
The invention relates to an iodinated CT contrast agent for non-invasive diagnosis of cachexia. This is possible by superior resolution of CT combined with CT contrast agent specific for the brown and/or beige adipose tissue (BAT).